OBJECTIVE: To determine the predictors of impaired cerebrovascular reactivity (CVR) and the value of CVR in predicting delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH). DESIGN: Prospective observational study. We evaluated CVR during the following intervals: period 1, SAH days 0 to 3; period 2, SAH days 4 to 7; and period 3, SAH days 8 to 10. Normal CVR was defined as an increase in mean blood flow velocity of at least 2% per 1-mm Hg increase in PCO(2). SETTING: Neurointensive care unit of the Columbia Presbyterian Medical Center. PATIENTS: Thirty-four consecutive patients with acute SAH who underwent measurement of changes in the middle cerebral artery mean blood flow velocity after carbon dioxide challenge. MAIN OUTCOME MEASURE: Occurrence of DCI. RESULTS: Delayed cerebral ischemia occurred in 10 patients (29%). Impaired CVR was more frequent in patients with a poor clinical grade on admission and at the time of examination. During period 1, there was only a trend toward lower CVR in patients who later developed DCI (1.1% vs 1.9% per 1-mm Hg increase in PCO(2); P = .07). However, those who developed DCI had progressively lower CVR during periods 2 (0.7%/mm Hg vs 2.1%/mm Hg; P < .001) and 3 (0.6%/mm Hg vs 2.4%/mm Hg; P < .001). Independent predictors of DCI included a decrease in CVR between periods 1 and 2 (P = .03) and a poor Hunt-Hess score (P = .04). Impaired CVR at any point had a sensitivity for subsequent DCI of 91% and a specificity of 49%. CONCLUSIONS: Impaired CVR in response to carbon dioxide challenge is frequent after SAH, particularly in patients with a poor clinical grade. Progressive loss of normal CVR identifies patients at high risk for DCI, and persistently normal reactivity implies a low risk.
OBJECTIVE: To determine the predictors of impaired cerebrovascular reactivity (CVR) and the value of CVR in predicting delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH). DESIGN: Prospective observational study. We evaluated CVR during the following intervals: period 1, SAH days 0 to 3; period 2, SAH days 4 to 7; and period 3, SAH days 8 to 10. Normal CVR was defined as an increase in mean blood flow velocity of at least 2% per 1-mm Hg increase in PCO(2). SETTING: Neurointensive care unit of the Columbia Presbyterian Medical Center. PATIENTS: Thirty-four consecutive patients with acute SAH who underwent measurement of changes in the middle cerebral artery mean blood flow velocity after carbon dioxide challenge. MAIN OUTCOME MEASURE: Occurrence of DCI. RESULTS:Delayed cerebral ischemia occurred in 10 patients (29%). Impaired CVR was more frequent in patients with a poor clinical grade on admission and at the time of examination. During period 1, there was only a trend toward lower CVR in patients who later developed DCI (1.1% vs 1.9% per 1-mm Hg increase in PCO(2); P = .07). However, those who developed DCI had progressively lower CVR during periods 2 (0.7%/mm Hg vs 2.1%/mm Hg; P < .001) and 3 (0.6%/mm Hg vs 2.4%/mm Hg; P < .001). Independent predictors of DCI included a decrease in CVR between periods 1 and 2 (P = .03) and a poor Hunt-Hess score (P = .04). Impaired CVR at any point had a sensitivity for subsequent DCI of 91% and a specificity of 49%. CONCLUSIONS: Impaired CVR in response to carbon dioxide challenge is frequent after SAH, particularly in patients with a poor clinical grade. Progressive loss of normal CVR identifies patients at high risk for DCI, and persistently normal reactivity implies a low risk.
Authors: Khalil M Yousef; Jeffrey R Balzer; Catherine M Bender; Leslie A Hoffman; Samuel M Poloyac; Feifei Ye; Paula R Sherwood Journal: J Neurosci Nurs Date: 2015-08 Impact factor: 1.230
Authors: Giovanni Muscas; Christiaan Hendrik Bas van Niftrik; Martina Sebök; Giuseppe Esposito; Luca Regli; Jorn Fierstra Journal: Acta Neurochir Suppl Date: 2021
Authors: Pedro Kurtz; Raimund Helbok; Sang-Bae Ko; Jan Claassen; J Michael Schmidt; Luis Fernandez; R Morgan Stuart; E Sander Connolly; Neeraj Badjatia; Stephan A Mayer; Kiwon Lee Journal: Neurocrit Care Date: 2014-04 Impact factor: 3.210
Authors: Molly G Bright; Manus J Donahue; Jeff H Duyn; Peter Jezzard; Daniel P Bulte Journal: J Cereb Blood Flow Metab Date: 2010-10-20 Impact factor: 6.200
Authors: Jharon N Silva; Oksana Polesskaya; Helen S Wei; Izad-Yar D Rasheed; Jeffrey M Chamberlain; Christopher Nishimura; Changyong Feng; Stephen Dewhurst Journal: Microcirculation Date: 2014-10 Impact factor: 2.628
Authors: Thomas Westermaier; Christian Stetter; Ekkehard Kunze; Nadine Willner; Judith Holzmeier; Judith Weiland; Stefan Koehler; Christopher Lotz; Christian Kilgenstein; Ralf-Ingo Ernestus; Norbert Roewer; Ralf Michael Muellenbach Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210